During Saturday’s ADA Diabetes Care Symposium, Juliana CN Chan, MB, ChB, MD, FRCP, discussed how a research-driven quality improvement initiative in Hong Kong evolved to help reform the delivery of diabetes care in China.
Sunday will feature more highly anticipated study announcements than any other day of the 79th Scientific Sessions. Here’s an ADAMeetingNews.org preview of the the four Sunday sessions featuring major study results.
The Centers for Medicare and Medicaid Services approved reimbursement for select continuous glucose monitoring (CGM) devices in 2017, but there are limited data on the use of CGM, insulin pumps, and other advanced diabetes technologies in older adults. Three clinical researchers, including Medha Munshi, MD, will share their insights, experience, and trial results during Sunday’s…
A panel of experts, including Jeffrey T. Kullgren, MS, MD, MPH, and Anne N. Thorndike, MD, MPH, will discuss ways to improve the effectiveness of diabetes interventions during Sunday’s symposium “Which Benefit Design and Behavioral Economic Interventions Can Be Used to Facilitate Diabetes Prevention?”
Emerging data suggest that the offspring of mothers who have diabetes during pregnancy are at increased risk of cognitive and neurodevelopmental disorders. These mental effects are in addition to better-known metabolic risks associated with maternal diabetes, according to Anny Xiang, PhD, and Peter Damm, MD.
Don’t forget to Wear Red Sunday to show your support of the ADA and our mission to prevent and cure diabetes, and to improve the lives of all people affected by diabetes. And it’s not too late to register for Sunday morning’s 5K@ADA run/walk through San Francisco.
Among vitamin D-sufficient adults at high risk for type 2 diabetes, vitamin D supplementation at a dose of 4000 IU per day did not significantly lower the risk of diabetes compared to placebo, according to the results of the Vitamin D and Type 2 Diabetes (D2d) Study – A Multicenter Randomized Controlled Trial for Diabetes…
Recent clinical trials studying the safety and efficacy of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with diabetes have created opportunities for collaboration with cardiologists and nephrologists, according to Jean-François Yale, MD, FRCPC.
Sanket Dhruva, MD, MS, and Steven E. Nissen, MD, MACC, addressed the ongoing controversy about how intensive therapy should be to lower low-density lipoprotein (LDL) cholesterol during Friday’s session “Is Very Aggressive Lowering of LDL Cholesterol Worthwhile?”
Recent clinical trials are changing the evidence base clinicians use to select the most appropriate treatment for type 2 diabetes. Tina Vilsbøll, MD, DMSc, will discuss adding a GLP-1 receptor agonist to metformin during Saturday’s Current Issues session “Choosing Evidence-Based Therapy for Type 2 Diabetes Mellitus with Cardiovascular Disease.”